Vir Biotechnology Return On Asset vs. Gross Profit
| VIR Stock | USD 7.86 0.24 3.15% |
For Vir Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vir Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vir Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vir Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vir Biotechnology over time as well as its relative position and ranking within its peers.
Vir |
Vir Biotechnology's Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vir Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.585 | Earnings Share (3.93) | Revenue Per Share 0.579 | Quarterly Revenue Growth (0.1) | Return On Assets (0.19) |
The market value of Vir Biotechnology is measured differently than its book value, which is the value of Vir that is recorded on the company's balance sheet. Investors also form their own opinion of Vir Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Vir Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vir Biotechnology's market value can be influenced by many factors that don't directly affect Vir Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vir Biotechnology Gross Profit vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vir Biotechnology's current stock value. Our valuation model uses many indicators to compare Vir Biotechnology value to that of its competitors to determine the firm's financial worth. Vir Biotechnology is rated below average in return on asset category among its peers. It is rated first in gross profit category among its peers . At this time, Vir Biotechnology's Gross Profit is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vir Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vir Gross Profit vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Vir Biotechnology |
| = | -0.19 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Vir Biotechnology |
| = | 1.03 B |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Vir Gross Profit Comparison
Vir Biotechnology is currently under evaluation in gross profit category among its peers.
Vir Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vir Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vir Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Vir Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Vir Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -815 K | -855.8 K | |
| Net Interest Income | 82.4 M | 86.5 M | |
| Interest Income | 82.4 M | 86.5 M | |
| Operating Income | -684.3 M | -650.1 M | |
| Net Loss | -600.7 M | -570.7 M | |
| Income Before Tax | -628.2 M | -596.8 M | |
| Non Operating Income Net Other | 148.4 M | 155.8 M | |
| Total Other Income Expense Net | 56.1 M | 63.9 M | |
| Net Income Applicable To Common Shares | 593.2 M | 622.9 M | |
| Net Loss | -615.1 M | -584.3 M | |
| Income Tax Expense | -13.1 M | -12.4 M | |
| Change To Netincome | 546.6 M | 573.9 M | |
| Net Loss | (4.59) | (4.36) | |
| Income Quality | 1.27 | 0.86 | |
| Net Income Per E B T | 0.98 | 1.02 |
Vir Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vir Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vir Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vir Biotechnology's important profitability drivers and their relationship over time.
Use Vir Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Vir Biotechnology Pair Trading
Vir Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vir Biotechnology position
In addition to having Vir Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.